CellaVision AB
C26
Company Profile
Business description
CellaVision AB is engaged in the business of supplying digital solutions for blood and body fluid analysis. Its solutions are based on digital image analysis technology, artificial intelligence, and information technology. The firm's product portfolio consists of CellaVision peripheral blood application, CellaVision advanced RBC application, and CellaVision remote review software. Its customers include mainly large hospital laboratories and commercial laboratories in North America, Europe and China, and Japan. The company derives the majority of its revenue from the sale of analyzers or software.
Contact
Mobilvagen 12
Lund22362
SWET: +46 464601600
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
250
Stocks News & Analysis
stocks
Unwarranted drop in ASX share
Jittery investors misinterpret an audit for an existential crisis.
stocks
After earnings, is Disney stock a buy, a sell, or fairly valued? -
Following the highly anticipated announcement of a new CEO, here’s what we think of Disney.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,281.80 | 97.30 | 1.06% |
| CAC 40 | 8,313.30 | 14.58 | -0.18% |
| DAX 40 | 24,934.09 | 53.76 | -0.22% |
| Dow JONES (US) | 50,188.14 | 52.27 | 0.10% |
| FTSE 100 | 10,426.33 | 72.49 | 0.70% |
| HKSE | 27,266.38 | 83.23 | 0.31% |
| NASDAQ | 23,102.47 | 136.20 | -0.59% |
| Nikkei 225 | 57,650.54 | 1,286.60 | 2.28% |
| NZX 50 Index | 13,507.28 | 60.91 | 0.45% |
| S&P 500 | 6,941.81 | 23.01 | -0.33% |
| S&P/ASX 200 | 9,014.80 | 98.80 | 1.11% |
| SSE Composite Index | 4,131.98 | 3.61 | 0.09% |